Implementing Genome-Driven Oncology

Publication date: 9 February 2017
Source:Cell, Volume 168, Issue 4
Author(s): David M. Hyman, Barry S. Taylor, José Baselga
Early successes in identifying and targeting individual oncogenic drivers, together with the increasing feasibility of sequencing tumor genomes, have brought forth the promise of genome-driven oncology care. As we expand the breadth and depth of genomic analyses, the biological and clinical complexity of its implementation will be unparalleled. Challenges include target credentialing and validation, implementing drug combinations, clinical trial designs, targeting tumor heterogeneity, and deploying technologies beyond DNA sequencing, among others. We review how contemporary approaches are tackling these challenges and will ultimately serve as an engine for biological discovery and increase our insight into cancer and its treatment.

Teaser

The era of precision oncology is driven by increased feasibility of sequencing tumor genomes and improving target validation as well as drug combinations for patient-specific treatment.


from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lruDle
via IFTTT